

# Michael Deininger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12025938/publications.pdf>

Version: 2024-02-01

35  
papers

9,029  
citations

279487

23  
h-index

377514

34  
g-index

35  
all docs

35  
docs citations

35  
times ranked

7865  
citing authors

#	ARTICLE	IF	CITATIONS
1	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. <i>Journal of Hematology and Oncology</i> , 2022, 15, 1.	6.9	33
2	Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 3176-3187.	3.3	8
3	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. <i>Blood</i> , 2021, 138, 2042-2050.	0.6	95
4	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. <i>Haematologica</i> , 2019, 104, 1935-1949.	1.7	93
5	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. <i>Leukemia Research</i> , 2019, 79, 38-44.	0.4	25
6	CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. <i>EBioMedicine</i> , 2019, 50, 111-121.	2.7	14
7	Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1311-1318.	1.2	14
8	The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. <i>Blood</i> , 2015, 126, 1551-1554.	0.6	151
9	Tyrosine Kinase Inhibitor-associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 4210-4218.	0.8	355
10	Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2015, 56, 1938-1948.	0.6	6
11	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. <i>Haematologica</i> , 2014, 99, 292-298.	1.7	38
12	The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. <i>British Journal of Haematology</i> , 2013, 161, 508-516.	1.2	83
13	Chronic Myelogenous Leukemia, Version 1.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1327-1340.	2.3	52
14	A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2012, 120, 3898-3905.	0.6	154
15	A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. <i>New England Journal of Medicine</i> , 2012, 366, 799-807.	13.9	1,738
16	Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment. <i>Leukemia Research</i> , 2011, 35, 831-833.	0.4	4
17	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 553-561.	3.0	362
18	Curing CML with imatinib—a dream come true?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 127-128.	12.5	31

#	ARTICLE	IF	CITATIONS
19	Clonal chromosomal abnormalities in CD34+/CD38 <sup>+</sup> hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors. <i>Leukemia</i> , 2010, 24, 1525-1528.	3.3	6
20	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009, 27, 6041-6051.	0.8	1,188
21	Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia. <i>Seminars in Oncology</i> , 2008, 35, S1-S17.	0.8	23
22	Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 3204-3212.	0.8	458
23	Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 604-609.	0.6	7
24	Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2007, 31, 1511-1520.	0.4	15
25	High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia. <i>Blood</i> , 2007, 110, 886-886.	0.6	3
26	Tyrosine Kinase Inhibitors. , 2007, , 477-508.		0
27	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , 2006, 108, 28-37.	0.6	1,117
28	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2006, 108, 1809-1820.	0.6	1,184
29	The effect of prior exposure to imatinib on transplant-related mortality. <i>Haematologica</i> , 2006, 91, 452-9.	1.7	87
30	Resistance to Imatinib: Mechanisms and Management. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3, 757-768.	2.3	49
31	The development of imatinib as a therapeutic agent for chronic myeloid leukemia. <i>Blood</i> , 2005, 105, 2640-2653.	0.6	1,137
32	Clonal Cytogenetic Abnormalities in Philadelphia Chromosome Negative Cells in Chronic Myeloid Leukemia Patients Treated with Imatinib. <i>Leukemia and Lymphoma</i> , 2004, 45, 2197-2203.	0.6	71
33	Src kinases in Ph <sup>+</sup> lymphoblastic leukemia. <i>Nature Genetics</i> , 2004, 36, 440-441.	9.4	14
34	Various Mechanisms Underlie Cytogenetic Refractoriness to Imatinib. <i>Blood</i> , 2004, 104, 2091-2091.	0.6	1
35	The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease. <i>Blood</i> , 1998, 92, 3362-3367.	0.6	413